Gerber Kawasaki Wealth & Investment Management bought a new stake in shares of Bausch Health Companies Inc (NYSE:BHC) in the first quarter, Holdings Channel reports. The firm bought 28,000 shares of the company’s stock, valued at approximately $691,000.
A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. acquired a new position in Bausch Health Companies during the 3rd quarter valued at about $223,173,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Bausch Health Companies by 0.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 8,452,664 shares of the company’s stock valued at $156,267,000 after purchasing an additional 75,175 shares during the period. Bank of Montreal Can boosted its stake in Bausch Health Companies by 28.2% during the 1st quarter. Bank of Montreal Can now owns 3,702,077 shares of the company’s stock valued at $91,441,000 after purchasing an additional 815,311 shares during the period. Orbimed Advisors LLC boosted its stake in Bausch Health Companies by 89.1% during the 4th quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock valued at $66,498,000 after purchasing an additional 1,696,400 shares during the period. Finally, Norges Bank acquired a new position in Bausch Health Companies during the 4th quarter valued at about $59,054,000. 54.70% of the stock is owned by hedge funds and other institutional investors.
In other Bausch Health Companies news, CEO Joseph C. Papa bought 30,000 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The stock was acquired at an average cost of $23.67 per share, with a total value of $710,100.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.87% of the stock is owned by corporate insiders.
BHC has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research note on Monday, January 28th. ValuEngine raised shares of Bausch Health Companies from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. Wells Fargo & Co upped their price target on shares of Bausch Health Companies from $9.00 to $25.19 and gave the stock an “underperform” rating in a research note on Tuesday, February 19th. HC Wainwright reaffirmed a “buy” rating on shares of Bausch Health Companies in a research note on Thursday, February 28th. Finally, Mizuho upped their price target on shares of Bausch Health Companies from $39.00 to $41.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Bausch Health Companies presently has a consensus rating of “Hold” and an average target price of $29.13.
Shares of NYSE:BHC traded up $0.10 during trading on Thursday, reaching $25.38. The company had a trading volume of 17,051 shares, compared to its average volume of 4,289,010. The firm has a market cap of $8.65 billion, a P/E ratio of 6.32, a P/E/G ratio of 0.57 and a beta of 0.55. Bausch Health Companies Inc has a twelve month low of $17.20 and a twelve month high of $28.45. The company has a current ratio of 1.08, a quick ratio of 0.83 and a debt-to-equity ratio of 8.61.
Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Monday, May 6th. The company reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.14. Bausch Health Companies had a negative net margin of 19.27% and a positive return on equity of 47.01%. The company had revenue of $2.02 billion during the quarter, compared to analyst estimates of $2.03 billion. During the same period in the prior year, the business posted $0.89 EPS. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. Equities research analysts forecast that Bausch Health Companies Inc will post 4.06 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This article was first reported by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.thestockobserver.com/2019/05/16/gerber-kawasaki-wealth-investment-management-takes-691000-position-in-bausch-health-companies-inc-bhc.html.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
See Also: What is the Quick Ratio?
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.